New hope for aggressive brain tumors: radioactive drug tested in small trial
NCT ID NCT06650605
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a radioactive drug called I-123 ATT001 in 7 adults with recurrent glioblastoma, a fast-growing brain cancer. The drug was given directly into the tumor cavity to see if it was safe and how it spread in the body. The study aimed to find the right dose and check for side effects, but it is not a cure and ongoing treatment is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA GLIOBLASTOMA MULTIFORME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University College London Hosptial
London, United Kingdom
-
University Hospital Southampton
Southampton, United Kingdom